Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Editas Medicine's Enterprise Value is $247.71 Mil.
Editas Medicine's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-119.86 Mil. Therefore, Editas Medicine's EV-to-OCF for today is -2.07.
The historical rank and industry rank for Editas Medicine's EV-to-OCF or its related term are showing as below:
EDIT'
s EV-to-OCF Range Over the Past 10 Years
Min: -168.89 Med: -3.79 Max: 510.05
Current: -2.07
During the past 13 years, the highest EV-to-OCF of Editas Medicine was 510.05. The lowest was -168.89. And the median was -3.79.
EDIT's EV-to-OCF is ranked worse than 58.04% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs EDIT: -2.07
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Editas Medicine's PE Ratio (TTM) for today is calculated as:
Editas Medicine's share price for today is $2.89.
Editas Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.750.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Editas Medicine EV-to-OCF Related Terms
Editas Medicine EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Editas Medicine's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Editas Medicine's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Editas Medicine's EV-to-OCF falls into.
Editas Medicine's current Enterprise Value is $247.71 Mil.
Editas Medicine's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-119.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (EDIT) has a EV-to-OCF of -2.07 as of Aug. 11, 2026. According to the industry distribution chart, Editas Medicine ranks #816 out of 1406 companies in the Biotechnology industry, placing it in the top 58%.
Is Editas Medicine's EV-to-OCF too high?
Editas Medicine's current EV-to-OCF is -2.07. Based on the distribution chart, Editas Medicine ranks #816 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Editas Medicine has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's EV-to-OCF compare to BNTC and PBYI?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #816 out of 1406 companies for EV-to-OCF. This places Editas Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Editas Medicine's current EV-to-OCF is -2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.41, compared to a current price of $2.89 — trading 19.9% above its estimated fair value. The current EV-to-OCF is -2.07. Editas Medicine's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Editas Medicine (EDIT), the current EV-to-OCF is -2.07 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $2.89 is trading 19.9% above its estimated GF Value™ of $2.41.
GuruFocus considers Editas Medicine to be Modestly Overvalued.
Key valuation signals for EDIT:
EV-to-OCF: -2.07
GF Value™: $2.41 vs. price of $2.89 (19.9% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
65GF Score
Get the complete analysis for EDIT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
